Fifty-five years after the Controlled Substances Act of 1970 relegated psilocybin to Schedule I status—placing it alongside...
Treatment Innovations
In the high-stakes world of pharmaceutical development, where the average cost to bring a single drug to...
In a significant move to reshape the landscape of genomic research, Roche has officially launched the Axelios...
By Jonathan Gardner | Published June 29, 2026 In a move that signals the deepening shift of...
The global biotechnology sector is currently navigating a period of profound structural transformation. Following a multi-year cooling-off...
In a groundbreaking convergence of synthetic biology, machine learning, and advanced manufacturing, researchers at Hanyang University in...
As the biopharmaceutical industry moves through the midpoint of 2026, the global clinical research landscape is defined...
In the rapidly evolving landscape of metabolic medicine, Eli Lilly has reached a new milestone with its...
In a decisive move to curb the escalating threat of the Bundibugyo ebolavirus (BDBV) in the Democratic...
Eli Lilly and Company has solidified its dominant position in the global pharmaceutical market, leveraging groundbreaking Phase...
